Levetiracetam Morningside Healthcare (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A, which plays a crucial role in regulating neurotransmitter release. This binding modulates calcium‑dependent exocytosis, stabilising synaptic transmission and lowering neuronal hyper‑excitability that contributes to seizure generation.

The appropriate dose of levetiracetam is individualized by the prescribing clinician based on factors such as the patient’s age, weight, renal function, seizure type and response to therapy. No fixed regimen is provided here; the prescriber will set the dosage and any necessary adjustments.

Safety data for levetiracetam in pregnancy and lactation are limited. Clinicians must weigh the potential benefits for seizure control against any possible risks to the fetus or infant. If treatment is required, the prescriber will consider the risk‑benefit profile and may monitor the patient closely.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Levetiracetam is distinguished by its unique SV2A binding mechanism, which generally results in fewer drug‑enzyme interactions compared with many older antiepileptics such as carbamazepine or phenytoin. It is often favoured for its broad spectrum of activity and relatively predictable pharmacokinetics, though individual response and tolerability vary.

Levetiracetam Morningside Healthcare tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture and light, and ensure the container is tightly closed to maintain product stability.

Levetiracetam is administered orally, typically as a tablet taken with or without food. The exact dosing schedule—once daily, twice daily, or more—depends on the prescriber’s recommendation and the patient’s individual therapeutic needs.

Serious risks include severe allergic reactions (rash, swelling, breathing difficulties), significant mood or behavior changes such as depression or suicidal thoughts, and rare hematologic abnormalities like low blood cell counts. Patients should seek immediate medical attention if any of these symptoms occur.

Levetiracetam is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is also advised for patients with severe renal impairment who may require dose adjustment, and for those with a history of serious psychiatric disorders until evaluated by a healthcare professional.